Investor Information

News Release

August 2, 2022

Notice Regarding Decision on Termination and Dissolution of Business in Consolidated Subsidiaries, ActivX Biosciences, Inc.
August 2, 2022

First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Aug 2, 2022) - Supplementary Information
August 2, 2022

Summary of Consolidated Financial Results(For the first quarter ended June 30, 2022) [Japanese Standard]
June 17, 2022

KYORIN Signs Joint Development and License Agreement for Genetically modified Adipocyte, Treatment Agent for Fabry Disease
May 17, 2022

Notice of Resumption of Operation at Nishinihon Delivery Center
May 11, 2022

Notice of Reduction of Capital Reserve
May 11, 2022

Absorption Type Merger (Simplified Merger and Short-Form Merger) of Wholly Owned Subsidiary　KYORIN Pharmaceutical Co., Ltd., Change of Trade Name and Partial Amendment to Articles of Incorporation
May 11, 2022

Consolidated Financial Results for the Fiscal Year Ended March 31, 2022 (May 11, 2022) - Supplementary Information

Latest IR Events

First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2023

: Top Message

: Products Under Development

: IR Events

: Financial Information

: IR Library

: Stock Information

Annual Report 2021